Weekly Recap | TONG REN TANG +6.94%, most brokers rate it buyWeekly Review·Sep 5 at 04:49 AM01666-0.31%
New Progress in Centralized Procurement of Chinese Herbal Pieces: 41 Varieties Included, 300 Billion Market Landscape to ChangeWallstreetcn·Apr 14 at 12:17 PM01666-0.31%00570-0.39%
Tongrentang Healthcare Postpones Hong Kong IPO, Remains Committed to Timely Completion of Global Offering and ListingWallstreetcn·Mar 27 at 01:15 AM026670.00%01666-0.31%
With only six months left until July 1, 2026, the implementation of Article 75 of the National Medical Products Administration's "Special Regulations on the Registration of Traditional Chinese Medicine" is entering its final window period. This regulation, referred to in the industry as the "death clause" for proprietary Chinese medicines, clearly states that after three years of implementation starting from July 1, 2023, the contraindications in the instructions will be prohibitedWallstreetcn·Jan 27 at 10:41 AM512290+1.30%159929+0.86%
